Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin

BACKGROUND: In the randomised controlled trial ECHELON-2 (NCT01777152; January 2013), brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin and prednisone (CHP) demonstrated improved efficacy compared with CHOP (CHP and vincristine) in frontline CD30+ peripheral T-cell lymphoma (PTCL), an aggr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cranmer, Holly, Trueman, David, Evers, Elise, Woodcock, Fionn, Podkonjak, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596633/
https://www.ncbi.nlm.nih.gov/pubmed/36057890
http://dx.doi.org/10.1007/s41669-022-00349-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596633/
https://www.ncbi.nlm.nih.gov/pubmed/36057890
http://dx.doi.org/10.1007/s41669-022-00349-z

Ejemplares similares